» Articles » PMID: 38570506

Loss of CREBBP and KMT2D Cooperate to Accelerate Lymphomagenesis and Shape the Lymphoma Immune Microenvironment

Abstract

Despite regulating overlapping gene enhancers and pathways, CREBBP and KMT2D mutations recurrently co-occur in germinal center (GC) B cell-derived lymphomas, suggesting potential oncogenic cooperation. Herein, we report that combined haploinsufficiency of Crebbp and Kmt2d induces a more severe mouse lymphoma phenotype (vs either allele alone) and unexpectedly confers an immune evasive microenvironment manifesting as CD8 T-cell exhaustion and reduced infiltration. This is linked to profound repression of immune synapse genes that mediate crosstalk with T-cells, resulting in aberrant GC B cell fate decisions. From the epigenetic perspective, we observe interaction and mutually dependent binding and function of CREBBP and KMT2D on chromatin. Their combined deficiency preferentially impairs activation of immune synapse-responsive super-enhancers, pointing to a particular dependency for both co-activators at these specialized regulatory elements. Together, our data provide an example where chromatin modifier mutations cooperatively shape and induce an immune-evasive microenvironment to facilitate lymphomagenesis.

Citing Articles

Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies.

Yang J, Zhou F, Luo X, Fang Y, Wang X, Liu X Cell Death Discov. 2025; 11(1):84.

PMID: 40032852 PMC: 11876437. DOI: 10.1038/s41420-025-02366-3.


Dysregulation of the p300/CBP histone acetyltransferases in human cancer.

Xu L, Xuan H, Shi X Epigenomics. 2025; 17(3):193-208.

PMID: 39929233 PMC: 11812348. DOI: 10.1080/17501911.2024.2447807.


Mapping in silico genetic networks of the KMT2D tumour suppressor gene to uncover novel functional associations and cancer cell vulnerabilities.

Takemon Y, Pleasance E, Gagliardi A, Hughes C, Csizmok V, Wee K Genome Med. 2024; 16(1):136.

PMID: 39578878 PMC: 11583415. DOI: 10.1186/s13073-024-01401-9.


Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review.

Masnikosa R, Cvetkovic Z, Piric D Int J Mol Sci. 2024; 25(21).

PMID: 39518937 PMC: 11545713. DOI: 10.3390/ijms252111384.


Follicular lymphoma research: an open dialogue for a collaborative roadmap.

Collin M, Gagey G, Shanmugam V, Louissaint Jr A, Okosun J, Sarkozy C Histopathology. 2024; 86(1):79-93.

PMID: 39468961 PMC: 11648361. DOI: 10.1111/his.15344.

References
1.
Schmitz R, Wright G, Huang D, Johnson C, Phelan J, Wang J . Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 378(15):1396-1407. PMC: 6010183. DOI: 10.1056/NEJMoa1801445. View

2.
Wright G, Huang D, Phelan J, Coulibaly Z, Roulland S, Young R . A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020; 37(4):551-568.e14. PMC: 8459709. DOI: 10.1016/j.ccell.2020.03.015. View

3.
Lacy S, Barrans S, Beer P, Painter D, Smith A, Roman E . Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 2020; 135(20):1759-1771. PMC: 7259825. DOI: 10.1182/blood.2019003535. View

4.
Kang-Decker N, Tong C, Boussouar F, Baker D, Xu W, Leontovich A . Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 insufficiency. Cancer Cell. 2004; 5(2):177-89. DOI: 10.1016/s1535-6108(04)00022-4. View

5.
Figueroa M, Abdel-Wahab O, Lu C, Ward P, Patel J, Shih A . Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18(6):553-67. PMC: 4105845. DOI: 10.1016/j.ccr.2010.11.015. View